UK

On May 19, 2021, Academic Health Science Networks (AHSNs) issued a review of spread and adoption approaches for innovations in the health sector. The study highlights the complexity of spread work, the diversity of approaches, the influential factors and provides recommendations for the future.

On May 17, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering the period January 20, 2021 - April 20, 2021). One new Clinical Commissioning Policy related to radiotherapy was added to the work program, and four new policies related to radiotherapy were published in the period from January 20, 2021, to April 20, 2021. Two policies related to heart valve procedures and extracorporeal treatment were discontinued.

On April 29, 2021, the National Institute for Health Research (NIHR) HTA Programme opened NICE Rolling Call for first-stage applications that should meet research recommendations provided by NICE guidance published from 2015 onwards. The first-stage application deadline is September 01, 2021.

In April 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (repetitive short-pulse transscleral cyclophotocoagulation for glaucoma, deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults, and Melphalan chemosaturation for primary or metastatic cancer in the liver) and two Medtech Innovation Briefings (microINR for anticoagulation therapy and RenalSense Clarity RMS for acute kidney injury), and two clinical guidelines (for atrial fibrillation and chronic pain in over 16s).

On May 10, 2021, NICE announced the update of the evidence standards framework (ESF) for digital health technologies with changes in response to an ESF user survey that ran from October to December 2019. Furthermore, NICE launched a new Office for Digital Health to coordinate its digital health activities and strategic projects and manage collaboration with external partners.

In late April 2021, NHSX released a "2020-21: A year in the life of the NHS AI Lab" report representing NHS Artificial Intelligence Laboratory (AI Lab) achievements and work progress. Among other things, NHSX published results of the 2021 AI in Health and Care Survey, which shows that the diagnostic area remains the most popular for AI-based technologies compared to 2019.

On May 10, 2021, NHS Artificial Intelligence Laboratory (AI Lab) announced an open call to test AI-driven COVID-19 models using the National COVID-19 Chest Imaging Database (NCCID), collected over 40,000 X-rays, CT, and MRI images from people with and without coronavirus. The NHS AI Lab is now inviting research institutions and technology companies that develop AI-driven models using COVID-19 chest imaging data. The deadline for applications is May 28, 2021.

In April 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0176 and 0073 with changes to be implemented not later than August 01, 2021. Four new procedure codes related to men's health and breast surgery and one new companion diagnostic code were introduced.

The National Institute for Health and Care Excellence (NICE) is currently developing health technology assessments concerning eHealth technologies in its Medical Technologies Guidance, Diagnostic Guidance, and Medtech Innovation Briefing programs. As of late April 2021, there are thirteen ongoing assessments.

On April 19, 2021, NICE has presented a new 5-year strategic plan at the virtual event. NICE provided clarifications and answered the questions on its strategy for 2021 to 2026 published in April that identified key trends and four strategic pillars indicating the significant changes NICE wants to make.

On March 31, 2021, NICE published Technology Appraisal Guidance on selective internal radiation therapies (SIRT) for treating hepatocellular carcinoma (HCC). Technology Appraisal is the only NICE program that has a direct link with the acceptance of technologies by payers. Payers need to implement the recommended technologies within three months after the publication of the guidance. Medical devices are very rarely evaluated within the Technology Appraisal program. SIR-Spheres and TheraSphere were recommended to treat unresectable advanced HCC under certain conditions, while QuiremSpheres was not recommended.

Healthcare Improvement Scotland develops HTAs and clinical guidelines to support decision-making. In the first quarter of 2021, Healthcare Improvement Scotland published assessments of targeted screening for early lung cancer in adults at high risk, gammaCore for cluster headache, and other topics, which mostly concern eHealth technologies.